U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C26H31N3O4
Molecular Weight 449.542
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of OPC-21268

SMILES

CC(=O)NCCCOC1=CC=C(C=C1)C(=O)N2CCC(CC2)N3C(=O)CCC4=C3C=CC=C4

InChI

InChIKey=KSNUCNRMDYJBKT-UHFFFAOYSA-N
InChI=1S/C26H31N3O4/c1-19(30)27-15-4-18-33-23-10-7-21(8-11-23)26(32)28-16-13-22(14-17-28)29-24-6-3-2-5-20(24)9-12-25(29)31/h2-3,5-8,10-11,22H,4,9,12-18H2,1H3,(H,27,30)

HIDE SMILES / InChI

Description
Curator's Comment: Description was created based on several sources, including http://adisinsight.springer.com/drugs/800000284 | https://www.ncbi.nlm.nih.gov/pubmed/8228734

OPC-21268, a non-peptide vasopressin V1 receptor antagonist, inhibited oxytocin- and vasopressin-induced contractions of myometrial strips from rats and from full-term pregnant women. OPC-21268, because of its non-peptide structure, is orally active and has been shown to lower blood pressure in a patient with congestive heart failure and in spontaneously hypertensive rats. It also attenuates vasopressin induced bradycardia in rabbits and pressor responses in rats. It has been demonstrated that OPC-21268 exerts its inhibitory action through binding to the vasopressin V1 receptors in rat liver and kidney. Finally, OPC-21268 was reported to be safe and non-toxic in healthy humans. Merck scientists showed that OPC-21268 had significant affinity for the rOTR and the hOTR. OPC-21268 has been in phase II clinical trials by Otsuka for the treatment of heart failure and hypertension. However, this research has been discontinued.

Approval Year

PubMed

PubMed

TitleDatePubMed
Characterization of the human oxytocin receptor stably expressed in 293 human embryonic kidney cells.
1995
The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathways.
1997 Oct
Vasopressin stimulates insulin release from islet cells through V1b receptors: a combined pharmacological/knockout approach.
2004 Mar
Impaired arginine-vasopressin-induced aldosterone release from adrenal gland cells in mice lacking the vasopressin V1A receptor.
2007 Jul 2
Patents

Sample Use Guides

Single oral administration of OPC-21268 (100 mg) in hypertensive patients on diets
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment: In human internal mammary arteries, the non-peptide V1 receptor antagonist, OPC-21268, failed to antagonize vasopressin-induced contraction at low concentrations and potentiated the contraction at higher concentrations (300 nmol/l, P < 0.05). In rat mesenteric resistance arteries, OPC-21268 (10 nmol/l) antagonized vasopressin-induced contraction
In endothelium-intact human coronary artery segments, OPC-21268 (3uM) induced a rightward shift of the vasopressin concentration-response curve.
Name Type Language
OPC-21268
Code English
Acetamide, N-[3-[4-[[4-(3,4-dihydro-2-oxo-1(2H)-quinolinyl)-1-piperidinyl]carbonyl]phenoxy]propyl]-
Systematic Name English
OPC 21268
Code English
Code System Code Type Description
PUBCHEM
114904
Created by admin on Sat Dec 16 11:04:48 GMT 2023 , Edited by admin on Sat Dec 16 11:04:48 GMT 2023
PRIMARY
CAS
131631-89-5
Created by admin on Sat Dec 16 11:04:48 GMT 2023 , Edited by admin on Sat Dec 16 11:04:48 GMT 2023
PRIMARY
FDA UNII
33U7944QCQ
Created by admin on Sat Dec 16 11:04:48 GMT 2023 , Edited by admin on Sat Dec 16 11:04:48 GMT 2023
PRIMARY
EPA CompTox
DTXSID70927295
Created by admin on Sat Dec 16 11:04:48 GMT 2023 , Edited by admin on Sat Dec 16 11:04:48 GMT 2023
PRIMARY